Samsung Biologics promotes new CEO from within to head next phase of rapid manufacturing expansion

Conner Mitchell

Riding a wave of red-hot investments in biologics, Samsung Biologics — the biopharma CDMO arm of the South Korean tech giant — is stringing together a series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Samsung Biologics promotes new CEO from within to head next phase of rapid manufacturing expansion

Conner Mitchell

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

Sam­sung Bi­o­log­ics pro­motes new CEO from with­in to head next phase of rapid man­u­fac­tur­ing ex­pan­sion

Conner Mitchell

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Samsung Biologics promotes new CEO from within to head next phase of rapid manufacturing expansion

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL